Related Experiment Video
Updated: Jul 17, 2026

Detection of MicroRNA Expression in the Kidneys of Immunoglobulin A Nephropathic Mice
Published on: July 8, 2020
Modulating the progression in IgA nephropathy
James C M Chan1, Howard Trachtman
1University of Vermont and the Barbara Bush Children's Hospital, Maine Medical Center, Portland, Me 04102-3175, USA. chanj@suscom-maine.net
Abstract:
IgA nephropathy affects almost 1% of the population and yet the diagnosis is often missed. This significant kidney disease is often progressive with 25% of the patients going on to end-stage kidney disease over the course of 25 years. This minireview describes the clinical presentations in children and young adults. Therapeutic options are discussed including angiotensin-converting enzyme blockade, steroids, cytotoxics, tonsillectomy, fish oil, vitamin E, singly or in combination, in order to modulate the rate of progression.
Insights
IgA nephropathy is a common kidney disease often diagnosed late. This review covers its presentation in young people and treatment options to slow disease progression.
Area of Science:
- Nephrology
- Immunology
Background:
- Immunoglobulin A (IgA) nephropathy affects nearly 1% of the global population.
- Diagnosis is frequently delayed, contributing to disease progression.
- A significant percentage (25%) of patients develop end-stage kidney disease within 25 years.
Purpose of the Study:
- To review the clinical presentations of IgA nephropathy in pediatric and young adult populations.
- To discuss current and potential therapeutic strategies for managing IgA nephropathy progression.
Main Methods:
- Literature review of clinical presentations and therapeutic interventions for IgA nephropathy.
- Synthesis of data on treatment efficacy and progression modulation.
Main Results:
- IgA nephropathy presents with diverse clinical manifestations in younger individuals.
- Multiple therapeutic avenues exist, including ACE inhibitors, steroids, and lifestyle interventions.
- Combination therapies may offer enhanced modulation of disease progression.
Conclusions:
- Early recognition of IgA nephropathy in children and young adults is crucial.
- A range of treatments can be employed to slow the progression of this kidney disease.
- Further research into optimal therapeutic combinations is warranted.
More Related Videos
14:18Dioscin Mediated IgA Nephropathy Alleviation by Inhibiting B Cell Activation In Vivo and Decreasing Galactose-Deficient IgA1 Production In Vitro
Published on: October 13, 2023
08:44Elucidation of the Material Basis of Yiqi Qingjie Formula Against IgA Nephropathy Using UHPLC-Q-Orbitrap HRMS Integrated with Network Pharmacology
Published on: May 19, 2026
Related Concept Videos
Glomerular Filtration Rate and its Regulation
GFR regulation involves two primary intrinsic controls: the myogenic and tubuloglomerular feedback mechanisms.
The myogenic...
Nephrotic Syndrome II : Assessment and Medical Management
Nephrotic Syndrome III : Nursing Management
Chronic Kidney Disease II: Clinical Manifestations
Chronic Kidney Disease III: Interprofessional Care
Diabetic Nephropathy